Abstract 407P
Background
CDK4/6 inhibitors plus endocrine therapy (ET) are the first-line (1L) standard for patients (pts) with HR+/HER2- advanced breast cancer (ABC). Data from clinical trials have shown high efficacy and good tolerability. Real World Studies are important to support these data and close potential knowledge gaps.
Methods
The prospective, non-interventional PERFORM study is going to enroll 1,900 pts from 320 sites across Germany and Austria to gain further insights on effectiveness, tolerability, patient-reported outcomes (PRO) and longitudinal treatment patterns after 1L treatment with palbociclib + ET. In this second interim analysis (IA 2), response rates and dose modifications in the total population and in age-related subgroups (≥75 years vs <75 years) were investigated.
Results
Between 10/2020 and 09/2022, 938 pts were enrolled and 624 pts had a follow-up of >6 months and were evaluable for analysis. The median age was 68 years (range 33-89), 39% of pts had de novo ABC and 11% ECOG ≥2, at inclusion. 30% of patients were ≥75 years of age. Of these, 22% had an ECOG performance status of ≥2 at inclusion compared to 7% of pts <75 years. The rate of de novo ABC was higher in pts ≥75 years (44%) than pts <75 years (36%), whereas the number and distribution of metastases was comparable. Progression-free survival (PFS) rate at 12 months was 71.7%; overall response rate (ORR) and clinical benefit rate (CBR) were 33.2% and 57.4%, respectively. Notably PFS, ORR and CBR were consistent across age groups. Dose modifications were performed in 74.1% of pts ≥75 years vs 61.5% of pts <75 years, respectively; >70% of pts in both subgroups are still on study treatment. Treatment discontinuation rates were comparable in both age groups (28.6% ≥75 years vs 27.3% <75 years), but (serious) adverse event as reason for treatment discontinuation was more frequent in pts ≥75 years (9.2% vs 3.0%).
Conclusions
The IA 2 of PERFORM shows comparable results regarding PFS, ORR and CBR of 1L treatment with palbociclib + ET in pts ≥ and <75 years, even though pts ≥75 years required dose modifications more frequently. These findings are in line with the data of clinical trials and support use of palbociclib based treatment independent of age.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Deutschland GmbH, Berlin, Germany.
Funding
Pfizer Deutschland GmbH, Berlin, Germany.
Disclosure
J.C. Radosa: Financial Interests, Personal and Institutional, Invited Speaker: Pfizer, Eisai, MSD, Roche, Novartis, Gedeon Richter, Lilly, Pierre Fabre, Daiichi Sankyo, Clovis; Financial Interests, Personal and Institutional, Advisory Board: Pfizer, Eisai, MSD, Roche, Novartis, Gedeon Richter, Lilly, Daiichi Sankyo, Clovis, Seagen; Financial Interests, Personal and Institutional, Funding: Medac GmbH, Daiichi Sankyo, Pfizer, Pierre Fabre; Financial Interests, Institutional, Principal Investigator: Pfizer. T. Fietz: Non-Financial Interests, Personal, Speaker’s Bureau: Novartis, Pfizer, AstraZeneca; Non-Financial Interests, Personal, Advisory Board: Novartis, Pfizer, AstraZeneca; Financial Interests, Institutional, Principal Investigator: Pfizer. J. Wilke: Financial Interests, Institutional, Principal Investigator: Pfizer. T. Decker: Financial Interests, Personal, Advisory Board: Novartis, IOMEDICO; Financial Interests, Personal, Invited Speaker: Novartis, Lilly. V. Petersen: Financial Interests, Institutional, Principal Investigator: Pfizer. M. Deryal: Financial Interests, Institutional, Principal Investigator: Pfizer. J. Knoblich: Financial Interests, Institutional, Principal Investigator: Pfizer. C. Losem: Non-Financial Interests, Personal, Advisory Board: Abbvie, Incyte; Non-Financial Interests, Personal, Member: DGHO, DKG; Financial Interests, Institutional, Principal Investigator: Pfizer. U. Rhein: Financial Interests, Institutional, Principal Investigator: Pfizer. B. Schöttker: Financial Interests, Institutional, Principal Investigator: Pfizer. D. Wrobel: Financial Interests, Personal, Invited Speaker: Novartis, Roche, Pierre Fabre; Financial Interests, Personal, Writing Engagement: Pierre Fabre; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Institutional, Principal Investigator: Pfizer. G. Pfeiler: Financial Interests, Personal, Invited Speaker: Amgen, Roche, Seagen, Novartis, Pfizer, Daiichi, MSD, Merck, AstraZeneca, Accord, Lilly; Financial Interests, Personal, Advisory Board: Amgen, Roche, Seagen, Novartis, Pfizer, Daiichi, MSD, Merck, AstraZeneca, Accord, Lilly; Financial Interests, Institutional, Research Grant: Amgen, Roche, Seagen, Novartis, Pfizer, Daiichi, MSD, Merck, AstraZeneca, Accord, Lilly; Financial Interests, Institutional, Principal Investigator: Pfizer. E. Zanucco: Financial Interests, Personal and Institutional, Full or part-time Employment: Pfizer; Financial Interests, Personal and Institutional, Stocks/Shares: Pfizer; Non-Financial Interests, Institutional, Project Lead: Pfizer; Non-Financial Interests, Institutional, Sponsor/Funding: Pfizer. J. Buncke: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. A. Adams: Financial Interests, Personal, Full or part-time Employment: Pfizer; Non-Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Institutional, Stocks/Shares: Pfizer; Non-Financial Interests, Institutional, Project Lead: Pfizer; Financial Interests, Institutional, Sponsor/Funding: Pfizer. E. Glastetter: Financial Interests, Personal and Institutional, Full or part-time Employment: Pfizer; Non-Financial Interests, Personal and Institutional, Full or part-time Employment: Pfizer; Financial Interests, Personal and Institutional, Stocks/Shares: Pfizer; Non-Financial Interests, Institutional, Project Lead: Pfizer; Non-Financial Interests, Institutional, Sponsor/Funding: Pfizer. R. Bartsch: Financial Interests, Personal, Invited Speaker: AstraZeneca, Seagen, Roche, Novartis, Eli-Lilly, Pierre-Fabre, Daiichi, Gilead, MSD, Pfizer, Eisai, Gruenenthal; Financial Interests, Personal, Advisory Board: Daiichi, AstraZeneca, Roche, Novartis, Eli-Lilly, Pierre-Fabre, MSD, Gilead, Seagen, Eisai, Gruenenthal; Financial Interests, Institutional, Funding, Investigator Initiated Trial: Daiichi; Financial Interests, Institutional, Coordinating PI, Drug support for investigator initiated trial: MSD. M.P. Lux: Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, AstraZeneca, Exact Sciences, Lilly; Non-Financial Interests, Personal, Writing Engagement: Pfizer, Exact Sciences, AstraZeneca; Financial Interests, Personal, Advisory Board: Pfizer, Novartis, AstraZeneca and Lilly ; Financial Interests, Personal, Advisory Role: Pfizer, Novartis, AstraZeneca, Exact Sciences, Agendia, Lilly; Financial Interests, Institutional, Principal Investigator: Pfizer; Financial Interests, Personal, Leadership Role: Pfizer; Non-Financial Interests, Personal, Leadership Role: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
358P - Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Presenter: Savannah Roy
Session: Poster session 03